Houte Hans van, Chief Financial Officer at Nurix Therapeutics, sold NRIX on Aug 4, 2026
Data as of Oct 16
▼ SELL$42.9K1,794 shares at $23.89Houte Hans van Chief Financial OfficerNRIX Nurix Therapeutics, Inc.
- Traded
- Aug 4, 2026
- Disclosed
- Aug 4, 2026
- Filed
- The same day
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
NRIX since disclosure
−1.1%
after the sale
Similar stocks (XLV) since disclosure
+9.0%
XLV — its sector index fund
Change in closing price from Aug 4, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLHoute Hans van Chief Financial OfficerNRIX Nurix Therapeutics, Inc.$73.1Kdisclosed Aug 4 · filed the same day